Autolus Therapeutics (NASDAQ:AUTL) Upgraded at The Goldman Sachs Group

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by analysts at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a $7.60 price target on the stock, up from their prior price target of $7.00. The Goldman Sachs Group’s price objective would indicate a potential upside of 146.75% from the company’s previous close.

A number of other equities analysts have also issued reports on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.15.

Autolus Therapeutics Stock Up 2.3 %

Shares of NASDAQ AUTL opened at $3.08 on Monday. The stock has a market cap of $819.56 million, a P/E ratio of -2.55 and a beta of 2.04. The firm’s 50-day simple moving average is $3.91 and its 200 day simple moving average is $3.99. Autolus Therapeutics has a fifty-two week low of $2.94 and a fifty-two week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the business earned ($0.26) EPS. On average, sell-side analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its position in shares of Autolus Therapeutics by 253.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after purchasing an additional 821,156 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Autolus Therapeutics in the third quarter worth about $1,082,000. Millennium Management LLC increased its position in shares of Autolus Therapeutics by 113.7% in the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after acquiring an additional 432,503 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in shares of Autolus Therapeutics by 27.4% during the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after acquiring an additional 925,000 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.